Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.49 |
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.44 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.44 |
| ▸ | CETP | P11597 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23533392 | 1.00 | EPHX2 (0.49) | EPHX2FAAHCNR1CNR2PPARA | |
| SCHEMBL23533340 | 1.00 | EPHX2 (0.49) | EPHX2FAAHCNR1CNR2PPARA | |
| SCHEMBL11895830 | 0.98 | EPHX2 (0.47) | EPHX2FAAHCNR1CNR2PPARA | |
| SCHEMBL11895832 | 0.98 | EPHX2 (0.47) | EPHX2FAAHCNR1CNR2PPARA | |
| SCHEMBL14496882 | 0.94 | TDP1 (0.50) | EPHX2FAAHCNR1CNR2PPARA | |
| SCHEMBL14496883 | 0.94 | TDP1 (0.50) | EPHX2FAAHCNR1CNR2PPARA | |
| SCHEMBL9197255 | 0.94 | TDP1 (0.50) | EPHX2FAAHCNR1CNR2PPARA | |
| SCHEMBL9197227 | 0.94 | TDP1 (0.50) | EPHX2FAAHCNR1CNR2PPARA | |
| SCHEMBL23533264 | 0.92 | EPHX2 (0.47) | EPHX2FAAHCNR1CNR2TSHR | |
| SCHEMBL23533267 | 0.92 | EPHX2 (0.47) | EPHX2FAAHCNR1CNR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230107538-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2023-04-06 | — | — | US | disclosed |
| US-20230107538-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2023-04-06 | — | — | US | disclosed |
| EP-4076649-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2022-10-26 | — | — | EP | disclosed |
| CN-114828958-A | Cycloalkyl-containing carboxylic acids and use thereof | 里米诺生物科学有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2021124272-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | Liminal Biosciences Limited (GB) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230107538-A1 | CYCLOALKYL-CONTAINING CARBOXYLIC ACIDS AND USES THEREOF | HCCS, CCL11, BCAT1 | EPHX2 2009/4885FAAH 1612/4885CNR1 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.